AOC3 and sclerosing cholangitis: Surprisingly, no significant changes in inflammation and liver fibrosis were observed in patients with primary sclerosing cholangitis after treatment with anti-VAP-1 monoclonal antibody (timolumab, BTT1023) in a phase 2 clinical trial (Hirschfield et al., 2024b).